Aspen Aerogels, Inc. (NYSE:ASPN) Receives $12.67 Average PT from Analysts

Shares of Aspen Aerogels, Inc. (NYSE:ASPN) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $12.6667.

Several brokerages have issued reports on ASPN. Barclays dropped their target price on Aspen Aerogels from $6.00 to $4.00 and set an “underweight” rating for the company in a report on Friday, November 7th. Zacks Research lowered shares of Aspen Aerogels from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Monday, December 29th. Finally, Canaccord Genuity Group decreased their target price on shares of Aspen Aerogels from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 7th.

Aspen Aerogels Stock Down 2.4%

ASPN stock opened at $3.25 on Monday. The company has a market cap of $268.61 million, a price-to-earnings ratio of -0.87 and a beta of 2.94. The company has a current ratio of 3.94, a quick ratio of 3.33 and a debt-to-equity ratio of 0.28. Aspen Aerogels has a 12 month low of $2.80 and a 12 month high of $13.28. The firm has a 50-day moving average of $3.64 and a two-hundred day moving average of $5.96.

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Thursday, November 6th. The construction company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Aspen Aerogels had a negative return on equity of 0.20% and a negative net margin of 86.52%.The company had revenue of $73.02 million for the quarter, compared to analyst estimates of $73.42 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. The company’s revenue for the quarter was down 37.8% on a year-over-year basis. Aspen Aerogels has set its FY 2025 guidance at -4.150–4.050 EPS. As a group, analysts forecast that Aspen Aerogels will post 0.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Donald R. Young sold 56,845 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $3.23, for a total value of $183,609.35. Following the completion of the transaction, the chief executive officer directly owned 494,011 shares in the company, valued at approximately $1,595,655.53. This represents a 10.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Aspen Aerogels

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASPN. Gagnon Securities LLC acquired a new stake in shares of Aspen Aerogels in the second quarter valued at $11,243,000. Y Intercept Hong Kong Ltd purchased a new position in Aspen Aerogels during the 2nd quarter valued at about $484,000. Palogic Value Management L.P. boosted its holdings in Aspen Aerogels by 43.5% during the 2nd quarter. Palogic Value Management L.P. now owns 610,000 shares of the construction company’s stock valued at $3,611,000 after acquiring an additional 185,000 shares during the period. SG Americas Securities LLC grew its position in Aspen Aerogels by 98.6% in the 2nd quarter. SG Americas Securities LLC now owns 133,821 shares of the construction company’s stock valued at $792,000 after acquiring an additional 66,427 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Aspen Aerogels during the second quarter worth about $10,459,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.